首页 | 本学科首页   官方微博 | 高级检索  
     


Impact of anemia on short-term outcomes after TAVR: A subgroup analysis from the BRAVO-3 randomized trial
Authors:Victor Razuk MD  Anton Camaj MD  MS  Davide Cao MD  Johny Nicolas MD  Christian Hengstenberg MD  Samantha Sartori PhD  Zhongjie Zhang MPH  David Power MD  Frans Beerkens MD  Mauro Chiarito MD  Nicolas Meneveau MD  Christophe Tron MD  Nicolas Dumonteil MD  Julian D. Widder MD  Markus Ferrari MD  Roberto Violini MD  Pieter R. Stella MD  PhD  Raban Jeger MD  Prodromos Anthopoulos MD  Roxana Mehran MD  George D. Dangas MD  PhD
Affiliation:1. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA;2. Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria;3. Department of Cardiology, University Hospital Jean Minjoz, Besançon, France;4. Division of Cardiology, Rouen University Hospital, Rouen, France;5. Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France;6. Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany;7. Interventional Cardiology, Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany;8. Interventional Cardiology Unit, San Camillo Hospital, Rome, Italy;9. Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands;10. Department of Cardiology, University Hospital Basel, University of Basel, Switzerland;11. European Medical, Arena Pharmaceuticals Inc, Zurich, Switzerland
Abstract:
Keywords:anemia  bivalirudin  heparin  TAVI  TAVR
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号